A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product
Authors
- Hans C. Ebbers (ORCID: https://orcid.org/0000-0002-9553-9863)
- Xiaomei Leng (ORCID: https://orcid.org/0000-0002-0215-9176)
- Niamh Kinsella (ORCID: https://orcid.org/0009-0004-9071-4935)
- Paul Chamberlain (ORCID: https://orcid.org/0000-0002-8273-140X)
- Yinbo Zhou
- Xiaolei Yang (ORCID: https://orcid.org/0009-0007-5099-9464)
- Peter C. Taylor (ORCID: https://orcid.org/0000-0001-7766-6167)
- Wei Wei (ORCID: https://orcid.org/0000-0003-1691-9305)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Nuffield Orthopaedic Centre (GB)
- Artelia (France) (FR)
- University of Oxford (GB)
- Biogen (United Kingdom) (GB)
- Ta Solutions (China) (CN)
- Biogen (Netherlands) (NL)
- Biogen (Switzerland) (CH)
Publication Details
- Journal
- Rheumatology and Therapy
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1007/s40744-025-00760-y
- Citations
- 1
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Biogen